Development Of Guanylate Cyclase Activators For The Treatment Of Pulmonary Arterial Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$137,684.00
Summary
Pulmonary arterial hypertension (PAH) is a life threatening condition with few treatment options. It is marked by shortness of breath and reduced energy as a result of an unexplained constriction of the blood vessels in the lung. This results in reduced life expectancy. We are developing a new treatment that will relax the blood vessels in the lung to improve quality and length of life.
Use Of Snake Venom Prothrombin Activators In Blood Collection Tubes To Produce High Quality Serum To Improve Patient Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$284,706.00
Summary
The timely availability of high quality serum and plasma samples are of the utmost importance for accurate biochemical analysis in a clinical setting. This requirement is particularly true for patients on anti-clotting therapeutic agents such as warfarin and heparin. In this study we will employ potent prothrombin activators purified from snake venom to enhance the clotting efficiency of blood for serum preparation for biochemical analysis.
The Respire_ System: Portable Pulmonary Delivery Platform For Rapid, Flexible And Highly Efficient Treatment Of Elderly, Paediatric And Physically-Compromised Patients With Chronic Respiratory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$599,142.00
Summary
The development of a low-cost miniature drug delivery platform for the treatment of chronic respiratory diseases is proposed. The portable device has already been shown to be significantly more efficient than currently available asthma inhalers. In addition, the device offers the possibility of dose adjustment to account for patient variability, such as age and disease severity, as well as a reduction in patient intervention, thus making it more appropriate for patients unable to self-medicate.
Novel Soluble Guanylate Cyclase Activators For Pulmonary Artery Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$474,087.00
Summary
Pulmonary hypertension (elevated blood pressure in the lungs) is a life-threatening condition with few treatment options. We have recently identified a new class of drug that may improve blood vessel function in the lungs and thereby provide a new drug for the management of this group of patients.
Ultrasonic Blood Pressure Measurement On Implanted Biomedical Surfaces
Funder
National Health and Medical Research Council
Funding Amount
$170,250.00
Summary
The project would develop a prototype device reporting blood pressure on a biomedical implant surface. The device would extract data in real time from a standard ultrasound scanner that images the implant. The School of Mathematical Sciences at Monash University will be contracted to develop this ultrasound pressure sensor.
New Dynamometric Techniques For Predicting Glaucoma Progression
Funder
National Health and Medical Research Council
Funding Amount
$171,825.00
Summary
Glaucoma is a major cause of blindness in our community. The biggest risk factor for glaucoma is raised intraocular pressure. However, the exact cause of the disease remains unknown. Through our basic science studies in animals we have discovered that changes in blood flow in the vessels at the optic disk may be involved in the disease process. In recent clinical trials we discovered that the presence or absence of pulsations in the retinal veins at the disk was both an indicator of severity and ....Glaucoma is a major cause of blindness in our community. The biggest risk factor for glaucoma is raised intraocular pressure. However, the exact cause of the disease remains unknown. Through our basic science studies in animals we have discovered that changes in blood flow in the vessels at the optic disk may be involved in the disease process. In recent clinical trials we discovered that the presence or absence of pulsations in the retinal veins at the disk was both an indicator of severity and progression of glaucoma. This is a major breakthrough because there is no other means of predicting in which glaucoma patients vision loss will develop most rapidly. This information will be very helpful in deciding which patients should have the most agressive treatment to restore normal intraocular pressure. This project seeks to develop a new commercial device to make such an examination easy for any clinical ophthalmologist. The device allows the doctor to examine the vessels at the disk whilst applying slight pressure to the eye to temporarily raise intraocular pressure. A footswitch is pressed when the doctor sees the vessels pulsate. The required force is recorded by a laptop computer and the data stored along with the patients details. Now we have confirmed the ability of such a measurement to predict the rate of visual field loss in glaucoma, such a measurement will become much more widespread in clinical ophthalmology, offering a new and large scale opportunity for such instrumentation. Our device will be easy to operate, more comfortable for the patient, and will be of major diagnostic value in glaucoma clinics worldwide.Read moreRead less
Development Of Platelet-Targeted Nanoparticles For Magnetic Resonance Imaging Towards The Detection Of Thrombi/Emboli And Vulnerable Atherosclerotic Plaques
Funder
National Health and Medical Research Council
Funding Amount
$606,524.00
Summary
Heart attack, stroke and pulmonary embolism typically strike without warning and either kill patients or cause devastating disabilities. Currently, we do not have diagnostic methods to identify patients and the blood vessels at risk. We have developed a new innovative MRI nanoparticle directed against activated platelets for the detection of _at risk� blood vessels. The current funding is requested to optimise the manufacture of this targeted MRI nanoparticle and to undertake the animal studies ....Heart attack, stroke and pulmonary embolism typically strike without warning and either kill patients or cause devastating disabilities. Currently, we do not have diagnostic methods to identify patients and the blood vessels at risk. We have developed a new innovative MRI nanoparticle directed against activated platelets for the detection of _at risk� blood vessels. The current funding is requested to optimise the manufacture of this targeted MRI nanoparticle and to undertake the animal studies required to enter early stage clinical trials.Read moreRead less
Novel Single-chain Antibody-targeted Nanoparticles For Diagnosis Of Vascular Diseases In Magnetic Resonance Imaging
Funder
National Health and Medical Research Council
Funding Amount
$460,797.00
Summary
The aim of this project is to develop targeted imaging agents that seek out specific markers for various states of cardiovascular disease. These agents would provide a method for detecting the presence and level of atherosclerosis and thrombotic events. The targeted nanoparticles may provide a unique opportunity to detect very early plaques, the vulnerability of existing plaques and difficult to diagnose vessel blockages such as pulmonary embolism.